Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's ($AZN) MedImmune unit knows, those groups can backpedal. With the American Academy of Pediatrics backing new limits on its antiviral Synagis drug, the company is fighting back with sensational newspaper advertising. Report